NDAINTRAVENOUSPOWDER
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
12.1. Mechanism of Action Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), inhibits telomerase enzymatic activity and prevents telomere binding. Increased telomerase activity and human telomerase reverse…
Indications (1)
Clinical Trials (1)
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Started Oct 2012
80 enrolled
Primary MyelofibrosisSecondary MyelofibrosisMyeloid Malignancies
Loss of Exclusivity
LOE Date
Jun 16, 2039
161 months away
Patent Expiry
Jun 16, 2039
Exclusivity Expiry
Jun 6, 2031